Sept 3 (Reuters) - Knight Therapeutics Inc GUD.TO :
* KNIGHT THERAPEUTICS ANNOUNCES FILLING OF SUPPLEMENT TO A NEW DRUG SUBMISSION FOR NERLYNX® (NERATINIB) TO TREAT HER2-POSITIVE METASTATIC BREAST CANCER
* KNIGHT THERAPEUTICS INC - SNDS FOR NERLYNX IS SUPPORTED BY RESULTS OF PHASE III NALA TRIAL